Article
Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Therapeutic drug monitoring - 1 Aug 2010
Kuypers Dirk R J, Naesens Maarten, de Jonge Hylke, Lerut Evelyne, Verbeke Kristin, Vanrenterghem Yves
Abstract excerpt
OBJECTIVES: Prolonged calcineurin inhibitor maintenance therapy in kidney allograft recipients is complicated by the development of chronic irreversible drug-induced nephrotoxicity (CNIT). METHODS: In 304 de novo renal graft recipients, the association among tacrolimus exposure indices (dose, C(0), AUC(0-12h)), CYP3A5, CYP3A4 and ABCB1 polymorphisms, clinical covariables and de novo arteriolar hyalinization as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
